Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
February 23 2023 - 04:15PM
GlobeNewswire Inc.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, today
announced the appointment of R. Newcomb Stillwell to its Board of
Directors, to be effective as of March 15, 2023.
“We are pleased to welcome Newcomb to our Board
of Directors," said Seth Lederman, M.D., President and Chief
Executive Officer of Tonix. "Mr. Stillwell brings nearly four
decades of experience in corporate law, having practiced
exclusively at Ropes & Gray LLP, where he was the Co-Managing
Partner of the Boston office. His extensive advisory experience on
numerous transactions in the life science and healthcare sectors
will add meaningful value to Tonix’s Board.”
Mr. Stillwell said, “I’m excited to join the
Board of Tonix, and to work with its dynamic management team and
other Board members. I look forward to providing strategic guidance
and insights to help the Company continue its advancement of
numerous product candidates throughout the drug development
process.”
Mr. Stillwell was a partner at Ropes & Gray
LLP, an international law firm, where he spent approximately 38
years, principally advising private equity firms on acquisitions
and related matters, including life science and healthcare
investments. In addition, he served as the first chair of the
firm’s Private Equity Group. Mr. Stillwell received a J.D., cum
laude, from Harvard Law School and an A.B., magna cum laude, from
Princeton University.
Tonix Pharmaceuticals Holding
Corp.*
Tonix is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing
therapeutics to treat and prevent human disease and alleviate
suffering. Tonix’s portfolio is composed of central nervous system
(CNS), rare disease, immunology and infectious disease product
candidates. Tonix’s CNS portfolio includes both small molecules and
biologics to treat pain, neurologic, psychiatric and addiction
conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine
HCl sublingual tablet), is in mid-Phase 3 development for the
management of fibromyalgia with a new Phase 3 study launched in the
second quarter of 2022 and interim data expected in the second
quarter of 2023. TNX-102 SL is also being developed to treat Long
COVID, a chronic post-acute COVID-19 condition. Tonix initiated a
Phase 2 study in Long COVID in the third quarter of 2022. TNX-1300
(cocaine esterase) is a biologic designed to treat cocaine
intoxication and has been granted Breakthrough Therapy designation
by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated
in the second quarter of 2023. TNX-1900 (intranasal potentiated
oxytocin), a small molecule in development for chronic migraine, is
being studied in a potential pivotal Phase 2 study that initiated
enrollment in the first quarter of 2023 and for which interim data
is expected in the fourth quarter of 2023. TNX-601 ER (tianeptine
hemioxalate extended-release tablets) is a once-daily formulation
of tianeptine being developed as a potential treatment for major
depressive disorder (MDD) with a Phase 2 study expected to be
initiated in the first quarter of 2023. Tonix’s rare disease
portfolio includes TNX-2900 (intranasal potentiated oxytocin) for
the treatment of Prader-Willi syndrome. TNX-2900 has been granted
Orphan Drug designation by the FDA. Tonix’s immunology portfolio
includes biologics to address organ transplant rejection,
autoimmunity and cancer, including TNX-1500, which is a humanized
monoclonal antibody targeting CD40-ligand (CD40L or CD154) being
developed for the prevention of allograft and xenograft rejection
and for the treatment of autoimmune diseases. A Phase 1 study of
TNX-1500 is expected to be initiated in the second quarter of 2023.
Tonix’s infectious disease pipeline includes a vaccine in
development to prevent smallpox and monkeypox, TNX-801; a
next-generation vaccine to prevent COVID-19, TNX-1850; a platform
to make fully human monoclonal antibodies to treat COVID-19,
TNX-3600; and humanized anti-SARS-CoV-2 monoclonal antibodies,
TNX-3800; and a class of broad-spectrum small molecule oral
antivirals, TNX-3900. TNX-801, Tonix’s vaccine in development to
prevent smallpox and monkeypox, also serves as the live virus
vaccine platform or recombinant pox vaccine (RPV) platform for
other infectious diseases. A Phase 1 study of TNX-801 is expected
to be initiated in the second half of 2023.
*All of Tonix’s product candidates are
investigational new drugs or biologics and have not been approved
for any indication.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, risks
related to the failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations; delays and uncertainties caused
by the global COVID-19 pandemic; risks related to the timing and
progress of clinical development of our product candidates; our
need for additional financing; uncertainties of patent protection
and litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any pharmaceutical under development, there are significant risks
in the development, regulatory approval and commercialization of
new products. Tonix does not undertake an obligation to update or
revise any forward-looking statement. Investors should read the
risk factors set forth in the Annual Report on Form 10-K for the
year ended December 31, 2021, as filed with the Securities and
Exchange Commission (the “SEC”) on March 14, 2022, and periodic
reports filed with the SEC on or after the date thereof. All of
Tonix's forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 904-8182
Olipriya Das, Ph.D. (media)Russo
PartnersOlipriya.Das@russopartnersllc.com (646) 942-5588
Peter Vozzo (investors)ICR
Westwickepeter.vozzo@westwicke.com(443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to Jun 2023
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Jun 2022 to Jun 2023